Peter Nygren - Genetic Mutations

Author Information

Peter Nygren is a renowned researcher affiliated with the Department of Immunology, Genetics and Pathology at Uppsala University, located in Uppsala, Sweden. His work primarily focuses on cancer research, where he explores novel treatment strategies and the genetic basis of cancer therapy. His expertise is reflected through his extensive research contributions that span various aspects of oncology and genetics.

Research Contributions

Peter Nygren has significantly contributed to the field of oncology, especially in the development and evaluation of cancer therapies. His research includes exploring innovative treatment modalities such as radiosensitization and irreversible electroporation for cancer treatment. Notably, he has worked on pharmacogenetic screening to reduce adverse effects in cancer treatments and has been involved in several clinical trials, including those investigating the efficacy of drugs like mebendazole and eryaspase in gastrointestinal and pancreatic cancers. His work is pivotal in advancing personalized medicine approaches in cancer therapy.

Aliases

Peter Nygren is also known by the aliases "P Nygren" and "P. Nygren" in various publications and academic circles. These variations are commonly used in his published works and citations.

Publication and Citation Metrics

Metric	Value
Total Citation Count	8516
H-index	51
Total Paper Count	319

Publications:

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells

DOI: 10.3892/ol.2022.13243

Year: 2022

Ultrasound guided percutaneous irreversible electroporation for treatment of locally recurrent pancreatic cancer

DOI: 10.1016/J.HPB.2020.11.808

Year: 2021

[New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings].

DOI:

Year: 2021

Does exercise intensity matter for fatigue during (neo‐)adjuvant cancer treatment? The Phys‐Can randomized clinical trial

DOI: 10.1111/sms.13930

Year: 2021

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

DOI: 10.1038/s41598-021-88433-y

Year: 2021

TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

DOI: 10.1200/JCO.2020.38.15_SUPPL.TPS4666

Year: 2020

AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.

DOI: 10.1200/jco.2020.38.4_suppl.tps268

Year: 2020

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy

DOI: 10.1038/s41467-020-15111-4

Year: 2020

Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection

DOI: 10.21873/anticanres.14249

Year: 2020

Cocreated internet‐based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U‐CARE AdultCan randomized controlled trial

DOI: 10.1002/pon.5489

Year: 2020

What is the Future of Genetic Mutations in Agriculture?

What is Benzene?

How Can Lifestyle Modifications Help?

What are the advantages of using ZFNs?

How Do Mutations Cause Diseases?

What is the Role of Precision Medicine in This Context?

Can Insertion Mutations Be Repaired?

How Does Genetic Testing Help in Managing Cystic Fibrosis?

What Are the Future Directions in Studying Non-Coding Mutations?

How do Viral Vectors Work?

Partnered Content Networks

Relevant Topics